Current guidelines in the United States for managing patients with AS who are in stages 1–4 of kidney disease (with an eGFR) between 15 and 90+ mL/min/1.73 m2) emphasize the early initiation of treatment with ACE inhibitors or ARBs [31]. Here, ACE is linked to kidney disorder.